SCHEMBL9880216

SCHEMBL9880216

CC1OC(CO)C(C)C(C)C1OC(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 5/20 0.54
LGALS9 O00182 4/20 0.54
LGALS1 P09382 4/20 0.54
LGALS7; LGALS7B P47929 3/20 0.54
SELP P16109 8/20 0.41
LGALS8 O00214 2/20 0.41
RNASE1 P07998 1/20 0.40
SELE P16581 2/20 0.40
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
LGALS4 P56470 1/20 0.38
TSHR P16473 1/20 0.38
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19726119 1.00 LGALS3 (0.54) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP
SCHEMBL9880221 0.89 LGALS3 (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP
SCHEMBL12886326 0.89 LGALS3 (0.62) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP
SCHEMBL9880215 0.89 LGALS9 (0.45) LGALS3LGALS9LGALS1LGALS7; LGALS7BAPOBEC3A
SCHEMBL17773524 0.88 LGALS3 (0.53) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP
SCHEMBL18654216 0.87 LGALS9 (0.55) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP
SCHEMBL12150955 0.84 LGALS9 (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BTSHR
SCHEMBL17320700 0.84 LGALS9 (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BTSHR
SCHEMBL18874981 0.84 LGALS9 (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BTSHR
SCHEMBL12747029 0.84 LGALS9 (0.46) LGALS3LGALS9LGALS1LGALS7; LGALS7BTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883170-B2 Adjuvant WESTERN ILLINOIS UNIVERSITY RESEARCH FOUNDATION (US) 2014-11-11 US disclosed
US-20130158242-A1 ALPHA-SELECTIVE GLYCOSYLATION METHOD NATIONAL CHIAO TUNG UNIVERSITY (TW) 2013-06-20 US disclosed
US-20120136142-A1 Vaccine Compositions For Marburg Virus SOUTHERN RESEARCH INSTITUTE (US) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158242-A1 ALPHA-SELECTIVE GLYCOSYLATION METHOD SI, OGA, ALG8 LGALS3 1379/4885LGALS9 1257/4885LGALS1 1131/4885
US-20120136142-A1 Vaccine Compositions For Marburg Virus OSBPL3, OSBP2, CD81 LGALS3 93/4885LGALS9 281/4885LGALS1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.